You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Siponimod

Showing 1 - 25 of 32
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mayzent Onboarding of Secondary Progressive Multiple Sclerosis

Completed
  • Secondary Progressive Multiple Sclerosis
    • Camperdown, New South Wales, Australia
    • +1 more
    Apr 19, 2023

    Assessment of Pregnancy Outcomes in Patients Treated With

    Recruiting
    • Multiple Sclerosis
    • Siponimod
    • La Jolla, California
      Novartis Investigative Site
    Jan 20, 2023

    Multiple Sclerosis Trial (Siponimod)

    Available
    • Multiple Sclerosis
    • Siponimod
    • (no location specified)
    Sep 13, 2022

    Mayzent on SPMS Patients in a Long-term Non-interventional Study

    Recruiting
    • Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
    • Siponimod
    • Baden, Aargau, Switzerland
    • +8 more
    May 16, 2022

    Secondary Progressive Multiple Sclerosis Trial in Germany (BAF312, Baseline disease modifying therapies (DMTs))

    Active, not recruiting
    • Secondary Progressive Multiple Sclerosis
    • BAF312
    • Baseline disease modifying therapies (DMTs)
    • Mittweida, Sachsen, Germany
    • +9 more
    Aug 9, 2022

    Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

    Recruiting
    • Multiple Sclerosis
    • Diroximel Fumarate
    • +8 more
    • Eden Prairie, Minnesota
      OptumInsight
    Jan 9, 2023

    Multiple Sclerosis (MS) Trial in Worldwide (Fingolimod, Ofatumumab, Siponimod)

    Recruiting
    • Multiple Sclerosis (MS)
    • Little Rock, Arkansas
    • +55 more
    Jan 13, 2023

    Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

    Recruiting
    • Active Secondary Progressive Multiple Sclerosis
    • siponimod
    • Ancona, AN, Italy
    • +19 more
    Dec 27, 2022

    Secondary-progressive Multiple Sclerosis Trial in Buffalo (Mayzent, Ocrevus)

    Recruiting
    • Secondary-progressive Multiple Sclerosis
    • Buffalo, New York
      University at Buffalo, Buffalo General Hospital
    Oct 10, 2022

    Active Dermatomyositis Trial in Czechia, Japan, United States (BAF312, Placebo)

    Terminated
    Has Results
    • Active Dermatomyositis
    • Phoenix, Arizona
    • +8 more
    Dec 9, 2020

    Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,

    Recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • Early Highly Effective Therapies Group
    • Escalation Therapies Group
    • Aurora, Colorado
    • +30 more
    Jul 22, 2022

    Among Healthcare Professionals and MS Patients to Assess Their

    Recruiting
    • Multiple Sclerosis
      • Basel, Switzerland
        Novartis Investigative Site
      Mar 21, 2022

      COVID-19 Vaccine Response in Treated MS Patients

      Recruiting
      • Multiple Sclerosis
      • Healthy
      • Blood draw
      • Boston, Massachusetts
        Brigham MS Center
      Jul 26, 2022

      Phase III Trial With BAF312 in Secondary Progressive Multiple

      Completed
      • Secondary Progressive Multiple Sclerosis
      • Blood Draw
      • CSF collection by lumbar puncture (Optional)
      • Berkeley, California
      • +12 more
      Nov 5, 2020

      results Surveillance for Mayzent in SPMS Patients

      Recruiting
      • Secondary Progressive Multiple Sclerosis (SPMS)
      • Anjo, Aichi, Japan
      • +210 more
      Dec 22, 2022

      Relapsing Remitting Multiple Sclerosis Trial in Portland (3 mg Melatonin, 5 mg Melatonin)

      Active, not recruiting
      • Relapsing Remitting Multiple Sclerosis
      • 3 mg Melatonin
      • 5 mg Melatonin
      • Portland, Oregon
        Providence MS Center
      May 5, 2022

      Multiple Sclerosis COVID-19/Vaccination Treated With Ofatumumab

      Completed
      • Multiple Sclerosis
        • East Hanover, New Jersey
          Novartis
        Jul 14, 2023

        Multiple Sclerosis Trial in Boston (Electronic Pill Bottle)

        Completed
        • Multiple Sclerosis
        • Electronic Pill Bottle
        • Boston, Massachusetts
          Massachusetts General Hospital
        Jul 26, 2021

        Early Patients Initiating Ofatumumab for Treatment of Multiple

        Completed
        • Multiple Sclerosis
        • Ofatunumab
        • East Hanover, New Jersey
          Novartis Investigative Site
        Nov 7, 2022

        Renal Impairment Trial in Orlando, Bucuresti (BAF312)

        Completed
        • Renal Impairment
        • Orlando, Florida
        • +1 more
        Dec 6, 2020

        Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Trial in Warsaw (Cladribine Subcutaneous Injection, 0.9% Chloride

        Recruiting
        • Multiple Sclerosis, Secondary Progressive
        • Multiple Sclerosis
        • Cladribine Subcutaneous Injection
        • 0.9% Chloride Injection Sodium
        • Warsaw, Mazowieckie, Poland
          Institute of Psychiatry and Neurology
        Jul 26, 2023

        Multiple Sclerosis, Relapsing-Remitting Trial in Chisinau (IMCY-0141, Placebo, Dimethyl Fumarate)

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Chisinau, Moldova, Republic of
          Republican Clinical Hospital, ARENSIA Exploratory Medicine
        Jun 8, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in United States (Early Aggressive Therapy or Traditional Therapy)

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Early Aggressive Therapy or Traditional Therapy
        • Birmingham, Alabama
        • +51 more
        Jan 23, 2023

        Hepatic Impairment Trial in Balatonfured, Budapest, Moscow (BAF312)

        Completed
        Has Results
        • Hepatic Impairment
        • Balatonfured, Hungary
        • +2 more
        Dec 6, 2020

        Multiple Sclerosis Trial in Derby (Homologous booster, Heterologous booster)

        Recruiting
        • Multiple Sclerosis
        • Homologous booster
        • Heterologous booster
        • Derby, Connecticut
          Griffin Hospital
        Jan 23, 2022